年龄对华法林剂量、抗凝控制及出血风险的影响
本研究基于1498例前瞻性起始队列中的华法林使用者,按年龄分为年轻(<50岁)、中年(50-70岁)和老年(>70岁)三组,评估年龄对华法林剂量、PTTR及大出血风险的影响。结果显示,校正临床和遗传因素后,中年和老年患者华法林剂量需求分别较年轻患者降低10.6%,且PTTR更高(p<0.0001),但老年患者大出血绝对风险显著升高(p=0.016),校正后每增加一个年龄类别出血相对风险增加31%(p=0.026)。
要点
- 老年患者华法林剂量需求较年轻患者降低约10.6%,且PTTR更高。
- 尽管抗凝控制更好,老年患者大出血风险仍显著高于年轻患者。
- 年龄每增加一个类别,校正后出血相对风险增加31%。
核心结论
- 在真实世界环境中,老年患者尽管抗凝控制更佳,但大出血事件风险更高。
研究设计与样本
- 前瞻性起始队列研究,纳入1498例华法林使用者,按年龄分为年轻(<50岁)、中年(50-70岁)和老年(>70岁)三组。
主要发现
- 中年和老年患者华法林剂量需求分别较年轻患者降低10.6%(校正临床和遗传因素后)。
- 中年和老年患者PTTR高于年轻患者(p<0.0001),尽管INR评估次数更少(p<0.0001)。
- 与年轻患者相比,中年患者出血绝对风险边缘升高(p=0.08),老年患者显著升高(p=0.016)。
- 校正后,年龄每增加一个类别,出血相对风险增加31%(p=0.026)。
临床怎么用
- 临床应关注老年华法林使用者的大出血风险,即使其抗凝控制达标。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: We assessed the influence of age on warfarin dose, percentage time in target range (PTTR), and risk of major hemorrhage. DESIGN: Warfarin users recruited into a large prospective inception cohort study were categorized into three age groups: young (younger than 50 yrs), middle aged (50-70 yrs), and elderly (older than 70 yrs). The influence of age on warfarin dose and PTTR was assessed using regression analysis; risk of major hemorrhage was assessed using proportional hazards analysis. Models were adjusted for demographic, clinical, and genetic factors. SETTING: Two outpatient anticoagulation clinics. PARTICIPANTS: A total of 1498 anticoagulated patients. OUTCOMES: Warfarin dose (mg/day), PTTR, major hemorrhage. RESULTS: Of the 1498 patients, 22.8% were young, 44.1% were middle aged, and 33.1% were elderly. After accounting for clinical and genetic factors, compared with young warfarin users, warfarin dose requirements were 10.6% lower among the middle aged and an additional 10.6% lower for the elderly. Compared with young patients, middle-aged and elderly patients spent more time in target international normalized ratio (INR) range (p<0.0001), despite having fewer INR assessments (p<0.0001). Compared with young warfarin users, absolute risk of hemorrhage was marginally higher among the middle aged (p=0.08) and significantly higher among the elderly (p=0.016). Compared with young warfarin users, after adjustment, the relative risk of hemorrhage increased by 31% for each age category (p=0.026). CONCLUSIONS: In a real-world setting, despite achieving better anticoagulation control, elderly patients had a higher risk of major hemorrhagic events. As the population ages and the candidacy for oral anticoagulation increases, strategies that mitigate the elevated risk of hemorrhage need to be identified.
引用
- Shendre A, Parmar GM, Dillon C, et al. Influence of Age on Warfarin Dose, Anticoagulation Control, and Risk of Hemorrhage. Pharmacotherapy. 2018. PMID: 29393514. doi:10.1002/phar.2089
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。